Terns Pharmaceuticals to Attend June 2024 Investor Conferences

FOSTER CITY, Calif., May 30, 2024 -- Terns Pharmaceuticals, Inc. (Nasdaq: TERN), a clinical-stage biopharmaceutical company, is dedicated to developing small molecule product candidates for serious conditions such as cancer and obesity. The company announced that its senior management will participate in two major investor conferences in June 2024.

The first event is the Jefferies Global Healthcare Conference, scheduled for Wednesday, June 5, 2024, at 5:00 p.m. ET. It will take place at the Marriott Marquis in New York City and will feature a fireside chat format. The second event is the Goldman Sachs 45th Annual Global Healthcare Conference, set for Tuesday, June 11, 2024, at 3:20 p.m. ET. This session will also be a fireside chat and will be held at the Loews Miami Beach Hotel in Miami.

Terns Pharmaceuticals is focused on advancing a pipeline that includes an allosteric BCR-ABL inhibitor, a small molecule GLP-1 receptor agonist, and a THR-β agonist. They are also working on a preclinical GIPR modulator, with a specific focus on a GIPR antagonist candidate. 

The company's strategy in developing these therapeutics aims to address significant medical needs and improve patient outcomes in areas with substantial unmet needs.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!